This provider's $12.9M in total Medicare payments ranks in the 93th percentile of Clinical Laboratory providers nationally.
Medicare payments to this provider grew 32139% from 2019 to 2023.
85% of their billing comes from a single procedure code (K1034 — Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count).
AI-generated analysis based on Medicare payment data.
Notable: Payments increased 2549% in 2020
Year-over-year payment surges can indicate changes in practice volume, new services, or billing pattern shifts.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2019 | $46.32 | $40.53 | 1.14x | $5.79 | $25.8K | 636 | 4 |
| 2020 | $55.69 | $43.18 | 1.29x | $12.51 | $682.9K | 15.8K | 13 |
| 2021 | $56.90 | $39.92 | 1.43x | $16.98 | $822.8K | 20.6K | 24 |
| 2022 | $25.63 | $12.84 | 2.00x | $12.79 | $3.0M | 234.8K | 37 |
| 2023 | $24.00 | $11.76 | 2.04x | $12.24 | $8.3M | 706.8K | 2 |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 929.9K | $10.9M | $11.76 | 2.04x |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 8.7K | $717.8K | $82.95 | 1.65x |
| 87798 | Detection test by nucleic acid for organism, amplified probe technique | 15.0K | $526.9K | $35.02 | 1.21x |
| 87801 | Detection test by nucleic acid for multiple organisms, amplified probe(s) technique | 2.1K | $147.0K | $69.88 | 1.14x |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within | 5.9K | $146.9K | $24.98 | 1.33x |
| 87481 | Detection test for candida species (yeast), amplified probe technique | 1.5K | $51.1K | $34.98 | 1.20x |
| 87640 | Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique | 1.3K | $44.5K | $35.06 | 1.15x |
| 87651 | Detection test by nucleic acid for strep (streptococcus, group a), amplified probe technique | 801 | $27.9K | $34.88 | 1.35x |
| 87181 | Evaluation of antimicrobial drug (antibiotic, antifungal, antiviral), agar dilution method | 5.5K | $26.3K | $4.73 | 1.14x |
| 87637 | Detection test by multiplex amplified probe technique for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (covid-19), influenza virus types a and b, and respiratory syncytial virus | 162 | $23.1K | $142.35 | 1.61x |
| 87581 | Detection test by nucleic acid for mycoplasma pneumoniae (bacteria), amplified probe technique | 616 | $21.6K | $35.01 | 1.15x |
| 87486 | Detection test by nucleic acid for chlamydia pneumoniae, amplified probe technique | 602 | $21.1K | $35.02 | 1.13x |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 124 | $19.2K | $154.76 | 1.26x |
| 87653 | Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique | 445 | $15.7K | $35.24 | 1.22x |
| 87500 | Detection test by nucleic acid for vancomycin resistance strep (vre), amplified probe technique | 397 | $13.9K | $34.94 | 1.42x |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 121 | $13.6K | $112.69 | 2.53x |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 527 | $12.4K | $23.46 | 1.26x |
| 80307 | Testing for presence of drug, by chemistry analyzers | 200 | $12.3K | $61.31 | 1.75x |
| 87641 | Detection test by nucleic acid for staphylococcus aureus, methicillin resistant (mrsa bacteria), amplified probe technique | 330 | $11.6K | $35.05 | 1.20x |
| 87541 | Detection test by nucleic acid for legionella pneumophila (water borne bacteria), amplified probe technique | 285 | $10.0K | $35.06 | 1.20x |
This provider submits charges 1.95 times higher than what Medicare actually pays.
A markup ratio of 1.95x means for every $100 Medicare pays, this provider initially charges $195. This is lower than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Other Clinical Laboratory providers in GA for peer comparison.
| Provider | Location | Total Payments | Status |
|---|---|---|---|
| Quest Diagnostics Clinical Laboratories Inc | Tucker, GA | $599.2M | ⚠️ Flagged |
| Bakotic Pathology Associates, Llc | Alpharetta, GA | $87.9M | ✓ Clear |
| Clinical Laboratory Services, Inc. | Winder, GA | $60.1M | ✓ Clear |
| Lifebrite Laboratories, Llc | Brookhaven, GA | $48.1M | ✓ Clear |
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data